PMID- 31533075
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200416
IS  - 1872-7913 (Electronic)
IS  - 0924-8579 (Linking)
VI  - 54
IP  - 6
DP  - 2019 Dec
TI  - Ceftazidime/avibactam versus carbapenems for the treatment of infections caused 
      by Enterobacteriaceae: A meta-analysis of randomised controlled trials.
PG  - 809-813
LID - S0924-8579(19)30250-X [pii]
LID - 10.1016/j.ijantimicag.2019.09.007 [doi]
AB  - OBJECTIVES: Enterobacteriaceae are the most common pathogens in nosocomial and 
      community infections. Carbapenems are widely used as the most effective 
      antibacterial agents against Enterobacteriaceae. However, increasing use of 
      carbapenems has accelerated the emergence of carbapenem-resistant 
      Enterobacteriaceae. This was a systematic review of recently published data to 
      compare the clinical efficacy and safety of ceftazidime/avibactam (CAZ-AVI) and 
      carbapenems in the treatment of Enterobacteriaceae infections. Moreover, we also 
      attempted to assess whether it is feasible to treat Enterobacteriaceae infections 
      with CAZ-AVI instead of carbapenems. METHODS: A comprehensive search was 
      performed using Medline, Embase and Cochrane Library for randomised controlled 
      trials (RCTs) comparing the efficacy and safety of CAZ-AVI and carbapenems for 
      the treatment of Enterobacteriaceae infections. Clinical success, microbiological 
      success, adverse events (AEs), serious adverse events (SAEs) and mortality were 
      assessed as the main outcomes. RESULTS: Three RCTs (1186 patients) were included 
      in the meta-analysis. The meta-analysis showed that there were no significant 
      differences between CAZ-AVI and carbapenems in clinical success [risk difference 
      (RD) = 0.00, 95% confidence interval (CI) -0.06 to 0.06; P = 0.99], 
      microbiological success (RD = 0.07, 95% CI -0.04 to 0.18; P = 0.21) or AEs 
      (RD = 0.00, 95% CI -0.02 to 0.03; P = 0.81). SAEs with CAZ-AVI were numerically 
      higher than with carbapenems (RD = 0.02, 95% CI -0.00 to 0.04; P = 0.06). 
      CONCLUSION: CAZ-AVI is comparable with carbapenems in efficacy and safety for 
      Enterobacteriaceae infections. More high-quality and large-scale RCTs are needed 
      to further confirm the safety of CAZ-AVI. [PROSPERO ID: CRD42019116685.].
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Che, Haoyue
AU  - Che H
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, 28 Fu Xing Road, Beijing 100853, People's Republic of China.
FAU - Wang, Rui
AU  - Wang R
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, 28 Fu Xing Road, Beijing 100853, People's Republic of China.
FAU - Wang, Jin
AU  - Wang J
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, 28 Fu Xing Road, Beijing 100853, People's Republic of China.
FAU - Cai, Yun
AU  - Cai Y
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, 28 Fu Xing Road, Beijing 100853, People's Republic of China. Electronic 
      address: caicai_hh@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190915
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Azabicyclo Compounds)
RN  - 0 (Carbapenems)
RN  - 0 (Drug Combinations)
RN  - 0 (avibactam, ceftazidime drug combination)
RN  - 9M416Z9QNR (Ceftazidime)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Azabicyclo Compounds/*therapeutic use
MH  - Carbapenems/*therapeutic use
MH  - Ceftazidime/*therapeutic use
MH  - Drug Combinations
MH  - *Enterobacteriaceae
MH  - Enterobacteriaceae Infections/*drug therapy/microbiology
MH  - Humans
OTO - NOTNLM
OT  - Carbapenems
OT  - Ceftazidime/avibactam
OT  - Enterobacteriaceae
OT  - Meta-analysis
OT  - beta-Lactam/beta-lactamase inhibitor
EDAT- 2019/09/19 06:00
MHDA- 2020/04/17 06:00
CRDT- 2019/09/19 06:00
PHST- 2019/04/02 00:00 [received]
PHST- 2019/08/09 00:00 [revised]
PHST- 2019/09/11 00:00 [accepted]
PHST- 2019/09/19 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2019/09/19 06:00 [entrez]
AID - S0924-8579(19)30250-X [pii]
AID - 10.1016/j.ijantimicag.2019.09.007 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2019 Dec;54(6):809-813. doi: 
      10.1016/j.ijantimicag.2019.09.007. Epub 2019 Sep 15.